Recent Advances in Understanding and Managing Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction

Overview

Journal F1000Prime Rep

Specialty Biomedical Engineering

Date 2015 Jun 23

PMID 26097737

Citations 9

Authors

Uta Griesenbach

Eric W F W Alton

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis is the most common autosomal recessive genetic disease in Caucasians and has been extensively studied for many decades. The cystic fibrosis transmembrane conductance regulator gene was identified in 1989. It encodes a complex protein which has numerous cellular functions. Our understanding of cystic fibrosis pathophysiology and genetics is constantly expanding and being refined, leading to improved management of the disease and increased life expectancy in affected individuals.

Citing Articles

Regional brain tissue changes in patients with cystic fibrosis.

Roy B, Woo M, Vacas S, Eshaghian P, Rao A, Kumar R J Transl Med. 2021; 19(1):419.

PMID: 34627274 PMC: 8502335. DOI: 10.1186/s12967-021-03092-x.

Cystic Fibrosis Human Organs-on-a-Chip.

Ogden H, Kim H, Wikenheiser-Brokamp K, Naren A, Mun K Micromachines (Basel). 2021; 12(7).

PMID: 34202364 PMC: 8305167. DOI: 10.3390/mi12070747.

Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Chin K, Sarmiento M, Alvarez-Cabrera N, Norazmi M, Acosta A Eur J Clin Microbiol Infect Dis. 2019; 39(5):799-826.

PMID: 31853742 PMC: 7222044. DOI: 10.1007/s10096-019-03771-0.

Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies.

Santos-Carballal B, Fernandez Fernandez E, Goycoolea F Polymers (Basel). 2019; 10(4).

PMID: 30966479 PMC: 6415274. DOI: 10.3390/polym10040444.

Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers.

Garbuzenko O, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T J Control Release. 2019; 296:225-231.

PMID: 30677435 PMC: 6461390. DOI: 10.1016/j.jconrel.2019.01.025.

References

Naehrlich L, Ballmann M, Davies J, Derichs N, Gonska T, Hjelte L . Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros. 2013; 13(1):24-8. DOI: 10.1016/j.jcf.2013.08.006. View

Jain R, Ray J, Pan J, Brody S . Sex hormone-dependent regulation of cilia beat frequency in airway epithelium. Am J Respir Cell Mol Biol. 2011; 46(4):446-53. PMC: 3359952. DOI: 10.1165/rcmb.2011-0107OC. View

Boyle M, De Boeck K . A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2014; 1(2):158-63. DOI: 10.1016/S2213-2600(12)70057-7. View

Hirsh A, Molino B, Zhang J, Astakhova N, Geiss W, Sargent B . Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem. 2006; 49(14):4098-115. DOI: 10.1021/jm051134w. View

Kerem E, Konstan M, De Boeck K, Accurso F, Sermet-Gaudelus I, Wilschanski M . Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014; 2(7):539-47. PMC: 4154311. DOI: 10.1016/S2213-2600(14)70100-6. View

Pezzulo A, Tang X, Hoegger M, Abou Alaiwa M, Ramachandran S, Moninger T . Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012; 487(7405):109-13. PMC: 3390761. DOI: 10.1038/nature11130. View

Griesenbach U, Inoue M, Meng C, Farley R, Chan M, Newman N . Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Am J Respir Crit Care Med. 2012; 186(9):846-56. PMC: 3530223. DOI: 10.1164/rccm.201206-1056OC. View

Ford E . Trends in mortality from COPD among adults in the United States. Chest. 2014; 148(4):962-970. PMC: 4587987. DOI: 10.1378/chest.14-2311. View

Boucher R . Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007; 58:157-70. DOI: 10.1146/annurev.med.58.071905.105316. View

10.

Boyle M, Bell S, Konstan M, McColley S, Rowe S, Rietschel E . A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014; 2(7):527-38. DOI: 10.1016/S2213-2600(14)70132-8. View

11.

Sanders D, Li Z, Laxova A, Rock M, Levy H, Collins J . Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc. 2013; 11(1):63-72. PMC: 3972988. DOI: 10.1513/AnnalsATS.201309-303OC. View

12.

Jain M, Goss C . Update in cystic fibrosis 2013. Am J Respir Crit Care Med. 2014; 189(10):1181-6. DOI: 10.1164/rccm.201402-0203UP. View

13.

Goldstein W, DORING G . Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis. 1986; 134(1):49-56. DOI: 10.1164/arrd.1986.134.1.49. View

14.

Rogers C, Stoltz D, Meyerholz D, Ostedgaard L, Rokhlina T, Taft P . Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 2008; 321(5897):1837-41. PMC: 2570747. DOI: 10.1126/science.1163600. View

15.

Wang Y, Wrennall J, Cai Z, Li H, Sheppard D . Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. Int J Biochem Cell Biol. 2014; 52:47-57. DOI: 10.1016/j.biocel.2014.04.001. View

16.

Ferrari M, Cremonesi L . Genotype-phenotype correlation in cystic fibrosis patients. Ann Biol Clin (Paris). 1996; 54(6):235-41. View

17.

Borowitz D, Parad R, Sharp J, Sabadosa K, Robinson K, Rock M . Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 2009; 155(6 Suppl):S106-16. PMC: 6326077. DOI: 10.1016/j.jpeds.2009.09.003. View

18.

De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G . Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014; 13(6):674-80. DOI: 10.1016/j.jcf.2014.09.005. View

19.

Singh A, Schultz B, Katzenellenbogen J, Price E, Bridges R, Bradbury N . Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated chloride secretion. J Pharmacol Exp Ther. 2000; 295(1):195-204. View

20.

Chen J, Stoltz D, Karp P, Ernst S, Pezzulo A, Moninger T . Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell. 2010; 143(6):911-23. PMC: 3057187. DOI: 10.1016/j.cell.2010.11.029. View